Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Armistice Capital and Biopharmx Corp (BPMX)

Page 1 of 11

Biopharmx Corp (NYSEMKT:BPMX): Steven Boyd’s Armistice Capital filed an amended 13D.

You can check out Armistice Capital’s latest holdings and filings here.

Please follow Armistice Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Armistice Capital or update its stock holdings.

Steven Boyd
Steven Boyd
Armistice Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Armistice Capital 0 6,670,000 0 6,670,000 6,670,000 5.3%
Armistice Capital Master Fund Ltd 0 6,670,000 0 6,670,000 6,670,000 5.3%
Steven Boyd 0 6,670,000 0 6,670,000 6,670,000 5.3%
Steven Boyd
Steven Boyd
Armistice Capital

Page 1 of 11 – SEC Filing

UNITED
STATES

SECURITIES AND
EXCHANGE COMMISSION

WASHINGTON,
DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

BioPharmX Corporation
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
09072X101
(CUSIP Number)
November 20, 2017
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[X] Rule 13d-1(c)

[_] Rule 13d-1(d)

__________

* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required
in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Biopharmx Corp (NYSEMKT:BPMX)
Trade (NYSEMKT:BPMX) Now!
Page 1 of 11
Loading...